Seeking increased US backing, Anchiano delists from TASEThe company is currently focused on treating early-stage bladder cancer, but says the principle is applicable to many cancer types.Anchiano Therapeutics CEO Dr. Frank G. Haluska(photo credit: Courtesy)
